GH Research price target raised to $31 from $30 at Canaccord

Canaccord raised the firm’s price target on GH Research to $31 from $30 and keeps a Buy rating on the shares. The firm said they posted results with the key updates for us were that the company is on track to report top- line data from its Phase 2b trial for GH001 ( a proprietary inhaled formulation of 5-MeO- DMT or mebufotenin) in 3Q or 4Q24. The company also expects to complete the 6-month open-label extension (OLE) portion of this trial in 1Q25.